Grapiprant Oral Composition for PK Control and Animal Palatability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations of grapiprant, a prostaglandin E2 subtype 4 (EP4) receptor antagonist, face challenges in achieving optimal pharmacokinetic properties such as peak plasma concentration, time to reach maximum concentration (Tmax), half-life, and area under the plasma concentration curve (AUC), while also ensuring palatability for non-human animals to enhance compliance.
Innovation Solution
A pharmaceutical composition comprising grapiprant with specific excipients like lactose, sodium starch glycolate, microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate, copovidone, and poloxamer, administered at varying concentrations and frequencies, achieves a targeted Cmax and Tmax, and includes flavorants to improve palatability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If grapiprant is formulated with specific excipients and dosing regimens, then pharmacokinetic parameters (Cmax, Tmax, half-life, AUC) are optimized, but formulation complexity increases
Solution Approach 1:
The patent optimizes pharmacokinetic parameters by systematically adjusting formulation parameters including excipient types and concentrations (lactose, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, copovidone, colloidal silicon dioxide, poloxamer), dosing frequencies (once daily, twice daily, thrice daily), and dosage rates (1-10 mg/kg/day). This controlled variation of parameters achieves target Cmax (375-10000 ng/ml), Tmax (0.4-3.4 hours), and half-life values while managing formulation complexity.
Solution Approach 2:
The patent employs composite pharmaceutical formulations combining grapiprant with multiple excipients in specific ratios. The composition includes about 5%-15% grapiprant, 20%-80% lactose, 15%-80% microcrystalline cellulose, 1%-10% sodium starch glycolate, 1%-10% copovidone, 0.5%-3% magnesium stearate, 0.5%-4% poloxamer, and 0.1%-1% colloidal silicon dioxide. This composite approach optimizes drug release, absorption, and stability to achieve reliable pharmacokinetic parameters.
2Ease of operation
If flavorants are added to improve palatability, then animal compliance improves, but formulation complexity increases
Solution Approach 1:
The patent enhances local quality by incorporating flavorants (1%-30% of total composition, preferably 5%-15%) specifically to improve palatability and animal compliance. This targeted addition addresses the sensory properties of the formulation without fundamentally altering the core pharmaceutical composition, thereby improving ease of administration while maintaining controlled formulation complexity.
3Reliability
If grapiprant is administered at higher dosage rates, then therapeutic efficacy improves, but peak plasma concentration may exceed optimal ranges
Solution Approach 1:
The patent employs dynamic dosing strategies where dosage rates (1-10 mg/kg/day) and administration frequencies (once, twice, or thrice daily) are adjusted based on individual animal needs, pain severity, and inflammatory conditions. This dynamic approach allows therapeutic efficacy to be optimized while maintaining peak plasma concentrations within the target range of 375-10000 ng/ml, preventing both under-dosing and excessive concentration peaks.
Solution Approach 2:
The patent utilizes periodic administration regimens (once daily, twice daily, or thrice daily) to maintain grapiprant plasma concentrations within therapeutic windows. This periodic dosing ensures sustained therapeutic efficacy while allowing metabolism to occur between doses, preventing accumulation and excessive peak concentrations. The dosing interval is optimized based on the drug's half-life and target AUC values.
Data Source
AI summary
The present disclosure provides a method for treating pain or inflammation in a non-human animal in need thereof. The method comprises administering to a non-human animal a pharmaceutical composition comprising a therapeutically effective amount of grapiprant. Also provided herein are pharmaceutical compositions for treating pain or inflammation in a non-human animal in need thereof. The pharmaceutical compositions comprise a therapeutically effective amount of grapiprant and an excipient, including flavorants.